Entrada Therapeutics, Inc. (TRDA) stock
TRDANasdaqPharmaceutical PreparationsFiscal year ends December 31
$5.00−0.09 (-1.77%)
Close on Nov 16, 2026Market cap $194.68MP/E –Yield –
Entrada Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Entrada Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$134.67M. For fiscal 2025 it was -$128.51M. The highest annual figure on record is $139.80M in fiscal 2023.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$128.51M | – |
| FY2024 | Dec 31, 2024 | -$41.56M | -129.7% |
| FY2023 | Dec 31, 2023 | $139.80M | – |
| FY2022 | Dec 31, 2022 | -$93.79M | – |
| FY2021 | Dec 31, 2021 | -$50.86M | – |
| FY2020 | Dec 31, 2020 | -$25.57M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$32.46M | – |
| Q1 FY2026 | Mar 31, 2026 | -$41.70M | – |
| Q4 FY2025 | Dec 31, 2025 | -$32.20M | – |
| Q3 FY2025 | Sep 30, 2025 | -$28.31M | – |
| Q2 FY2025 | Jun 30, 2025 | -$29.49M | -174.0% |
| Q1 FY2025 | Mar 31, 2025 | -$38.51M | – |
| Q4 FY2024 | Dec 31, 2024 | -$31.61M | – |
| Q3 FY2024 | Sep 30, 2024 | -$24.27M | – |
| Q2 FY2024 | Jun 30, 2024 | $39.83M | – |
| Q1 FY2024 | Mar 31, 2024 | -$25.52M | -112.5% |
| Q4 FY2023 | Dec 31, 2023 | -$4.01M | – |
| Q3 FY2023 | Sep 30, 2023 | -$24.49M | – |
| Q2 FY2023 | Jun 30, 2023 | -$35.09M | – |
| Q1 FY2023 | Mar 31, 2023 | $203.40M | – |
| Q4 FY2022 | Dec 31, 2022 | -$27.30M | – |
| Q3 FY2022 | Sep 30, 2022 | -$27.48M | – |
| Q2 FY2022 | Jun 30, 2022 | -$18.01M | – |
| Q1 FY2022 | Mar 31, 2022 | -$20.99M | – |
| Q4 FY2021 | Dec 31, 2021 | -$20.54M | – |
| Q3 FY2021 | Sep 30, 2021 | -$14.08M | – |
| Q2 FY2021 | Jun 30, 2021 | -$7.91M | – |
| Q1 FY2021 | Mar 31, 2021 | -$8.34M | – |
| Q4 FY2020 | Dec 31, 2020 | -$6.62M | – |
See a number that looks wrong?